Omnicell (OMCL) Tops Q3 EPS by 5c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Omnicell Announces Financial Results for Third Quarter 2022
November 2, 2022 8:01 AM EDTGAAP and non-GAAP revenues of $348 million
GAAP net income per diluted share of $0.37
Non-GAAP net income per diluted share of $1.00
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2022 and updated 2022 guidance.
Randall Lipps, Chairman, President, Chief Executive Officer, and Founder of Omnicell, said, In the third quarter, we... More
